CBI News
01/12/2012
Mediwound Requests the EMA to Register the Drug NexoBird
27/02/2012
Extraordinary shareholders meeting called for March 13, 2012
24/01/2012
D-Pharm Terminates phase III clinical trial on the DP-b99
23/01/2012
Avraham intermediate report: successfully completes phase IIb Clinical Trial in Alzheimer patients
25/12/2011
CBI, Migdal and Harel have signed an agreement to establish Medical Device investment funds
14/12/2011
Clarification: CBI does not see TransPharma as a Substantial Portfolio company
14/12/2011
Eli Lilly Ends the licensing agreement and joint development with TransPharma
29/11/2011
CureTech begins phase II Clinical Trial in Metastatic Melanoma
22/11/2011
Andromeda phase III Clinical Trial in Diabetes Type I success
11/10/2011
Extrordinary shareholders meeting called for November 17, 2011
02/10/2011
Annual shareholders meeting called for October 25, 2011
02/08/2011
D-Pharm raises NIS 16.5 million by rights offering
03/07/2011
Trombotech begins Phase IIa Clinical Trial in Ischemic Stroke
31/05/2011
D-Pharm signs colaberation agreement with Nhwa regarding development of DP-VPA in China
30/05/2011
CBI raises NIS 73 million from options' exercise
17/05/2011
Curetech successfully completes Phase II Clinical Trial in Diffuse Large B-Cell Lymphoma
12/05/2011
CBI negotiates with Institutional Investors the formation of medical devices funds in total amount of USD 225 million
14/04/2011
D-Pharm recieves Fast Track approval from the FDA for DP-b99
05/03/2011
Curetech submits IND for Phase II Clinical Trial in Metastatic Melanoma to FDA
22/02/2011
CBI acquires additional 6% of Transpharma Medical Ltd.
20/02/2011
Andromeda ends patients' enrollment for Phase III clinical trial in Diabetes type I
17/02/2011
Curetech ends patients' enrollment for Phase II clinical trial for coloretal cancer
17/02/2011
Curetech begins Phae II clinical trial in Multiple Meyeloma
01/02/2011
Closing of the Collaboration agreement between Teva, Mediwound and Polyheal
16/01/2011
Gamida Cell starts Phase I clinical trial with Nicord
12/01/2011
Extraordinary shareholders meeting called for February 17, 2011
10/01/2011
D-Pharm submitted to ISA first darft of shelf prospectus
05/01/2011
Mediwound Submits IND for Pivotal Phase III Clinical Trial to FDA
27/12/2010
BioCancell's updtae regardingthe results of Phase I/II clinical trial in pancreatic cancer
11/11/2010
Extraordinary shareholders meeting called for December 19, 2010
04/11/2010
BioCancell successfully completes Phase I/II clinical trial in pancreatic cancer
31/10/2010
Mediwound submits NexoBrid application to EMA
15/09/2010
Migdal exercises option to acquire 2.85 million CBI shares for about NIS 40 million
11/09/2010
Collaboration agreement signed between Teva, Mediwound and Polyheal
05/09/2010
D-Pharm raises NIS 15.7 million for continued development of DP-VPA product
09/07/2010
Thrombotech announces Phase I clinical trial results
06/07/2010
Aposense IPO successfully completed on Tel Aviv stock exchange
06/07/2010
Mediwound announces final results of Phase III clinical trial in burn debriding
24/06/2010
MOU for collaboration signed between Teva, Mediwound and Polyheal
14/06/2010
Teva and CBI exercise option to acquire additional shares in Andromeda Biotech
27/05/2010
Andromeda announces first patient in for pivotal Phase III clinical trial in type 1 diabetes
03/05/2010
Biokine announces completion of Phase I/II clinical trial in cancer patients
15/04/2010
D-Pharm receives SPA
Home
|
Profile
|
Team
|
Portfolio
|
Contact Us
|
Disclaimer
All Rights Reserved to Clal Biotechnology Industries Ltd.
